Clinical Trial Update: Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients [NA]

View source ↗

Summary

A completed clinical trial evaluated growth hormone secretagogue MK-0677 (ibutamoren) and its effect on IGF-1 levels in patients with chronic kidney disease and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• MK-0677 (Ibutamoren) (ibutamoren)

Snippet

Sponsor: University of Virginia | Conditions: Chronic Kidney Disease, End Stage Renal Disease | NA | Status: COMPLETED | Results posted: 2012-01-06